Delivery Order SPE2DB25D3021-SPE2DB25FQYPB
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,894.36 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560 mcg/2.24 mL pen injections. The contract, which was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a firm fixed-price delivery order under a competitive, non-set-aside procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for teriparatide 560 mcg/2.24 mL pen injections, valued at $5,592.67 with a firm fixed price structure. The award, issued on August 22, 2025, with completion targeted for August 25, 2025, represents a non-set-aside competitive award for pharmaceutical supply fulfillment. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed...
- The Defense Logistics Agency awarded a delivery order valued at $12,997.91 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560 mcg/2.24 mL pen injections. This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of September 30, 2025. The contract represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 and extends through...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,156.03 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24ml pen injections, with a completion date of May 2, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the...
- The Defense Logistics Agency awarded a delivery order valued at $7,313.71 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24ml pen injections. This competitively awarded, firm fixed price contract with no set-aside designation is scheduled for completion by July 23, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement to support federal medical supply...
- The Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order on August 6, 2025, for the supply of Teriparatide 560 mcg/2.24 mL pen injections, valued at $13,541.58. This firm fixed-price, competitively awarded contract will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 7, 2025. The delivery order carries no set-aside designation and represents a routine...
- The Defense Logistics Agency awarded a $6,226.08 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Teriparatide 560mcg/2.24ml pen injectors. The contract represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of August 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $41,615.46 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24mL pen injections. The contract, issued on September 9, 2025, with an ultimate completion date of September 10, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 8, 2025, for the supply of Teriparatide 560 mcg/2.24 mL pen injections, with a ceiling value of $5,560.39. This is a firm fixed-price delivery order with an ultimate completion date of May 9, 2025, and represents a non-competitive set-aside award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $26,852.75 delivery order to AmerisourceBergen Drug Corp for the supply of Teriparatide 560 mcg/2.24 mL pen injections. This contract represents a firm fixed-price delivery order with an ultimate completion date of June 3, 2025, and was competitively awarded without set-aside provisions. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Teriparatide is a recombinant human parathyroid hormone used in...
- SPE2DB25D3021Indefinite Delivery Contract
- SPE2DB25D3021-SPE2DB25FQYPBDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24ml pen injections, valued at $22,413.75 under a firm fixed-price contract. The award was made on May 27, 2025, with an ultimate completion date of May 28, 2025, and represents a competitive, non-set-aside procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor within the federal medical procurement supply chain, particularly for military and veteran healthcare systems. The SPE2DX IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including support to the Defense Health Agency and U.S. Coast Guard. The current delivery order for Teriparatide, a bone-building medication used in osteoporosis treatment, exemplifies the company's role in fulfilling specialized pharmaceutical requirements across the federal health system. All of AmerisourceBergen's reviewed contract awards have been competitively awarded with firm fixed pricing, demonstrating the company's capability to meet federal procurement standards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.4k | 5/27/25 |